You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameTriflupromazine
Accession NumberDB00508  (APRD00465)
TypeSmall Molecule
GroupsApproved, Vet Approved
DescriptionA phenothiazine used as an antipsychotic agent and as an antiemetic. [PubChem]
Structure
Thumb
Synonyms
10-(3-(Dimethylamino)propyl)-2-(trifluoromethyl)phenothiazine
2-(Trifluoromethyl)promazine
2-Trifluoromethyl-10-(gamma-dimethylaminopropyl)phenothiazine
Fluopromazine
Triflupromazin
Triflupromazina
Triflupromazine
Triflupromazinum
External Identifiers
  • MC 4703
  • SKF 4648-A
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
VesprinBristol Myers Squibb
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Triflupromazine Hydrochloride
1098-60-8
Thumb
  • InChI Key: FTNWXGFYRHWUKG-UHFFFAOYSA-N
  • Monoisotopic Mass: 388.098782
  • Average Mass: 388.88
DBSALT001039
Categories
UNIIRO16TQF95Y
CAS number146-54-3
WeightAverage: 352.417
Monoisotopic: 352.122103923
Chemical FormulaC18H19F3N2S
InChI KeyXSCGXQMFQXDFCW-UHFFFAOYSA-N
InChI
InChI=1S/C18H19F3N2S/c1-22(2)10-5-11-23-14-6-3-4-7-16(14)24-17-9-8-13(12-15(17)23)18(19,20)21/h3-4,6-9,12H,5,10-11H2,1-2H3
IUPAC Name
dimethyl({3-[2-(trifluoromethyl)-10H-phenothiazin-10-yl]propyl})amine
SMILES
CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(C=C2)C(F)(F)F
Pharmacology
IndicationUsed mainly in the management of psychoses. Also used to control nausea and vomiting.
Structured Indications Not Available
PharmacodynamicsTriflupromazine is a member of a class of drugs called phenthiazines, which are dopamine D1/D2 receptor antagonists. Phenothiazines are used to treat serious mental and emotional disorders, including schizophrenia and other psychotic disorders. It reduces anxiety, emotional withdrawal, hallucinations, disorganized thoughts, blunted mood, and suspiciousness. Triflupromazine is used particularly to control violent behavior during acute episodes of psychotic disorders. It can also be used to control severe nausea and vomiting, severe hiccups, and moderate to severe pain in some hospitalized patients. Triflupromazine acts on the central nervous system.
Mechanism of actionTriflupromazine binds to the dopamine D1 and dopamine D2 receptors and inhibits their activity. The mechanism of the anti-emetic effect is due predominantly to blockage of the dopamine D2 neurotransmitter receptors in the chemoreceptor trigger zone (CTZ) and vomiting centre. Triflupromazine blocks the neurotransmitter dopamine and the vagus nerve in the gastrointestinal tract. Triflupromazine also binds the muscarinic acetylcholine receptors (M1 and M2) and the tryptamine D receptors (5HT2B).
TargetKindPharmacological actionActionsOrganismUniProt ID
D(1A) dopamine receptorProteinyes
antagonist
HumanP21728 details
D(2) dopamine receptorProteinyes
antagonist
HumanP14416 details
5-hydroxytryptamine receptor 2BProteinyes
antagonist
HumanP41595 details
Muscarinic acetylcholine receptor M1Proteinyes
antagonist
HumanP11229 details
Muscarinic acetylcholine receptor M2Proteinyes
antagonist
HumanP08172 details
Related Articles
AbsorptionAbsorption may be erratic and peak plasma concentrations show large interindividual differences.
Volume of distributionNot Available
Protein bindingVery high (90% or more).
Metabolism

Hepatic.

Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicitySymptoms of overdose include agitation, coma, convulsions, difficulty breathing, difficulty swallowing, dry mouth, extreme sleepiness, fever, intestinal blockage, irregular heart rate, low blood pressure, and restlessness.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneThe risk or severity of adverse effects can be increased when Triflupromazine is combined with 1,1,1,2 Tetrafluoroethane.Investigational
2,5-Dimethoxy-4-ethylamphetamineTriflupromazine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
3,4-MethylenedioxyamphetamineTriflupromazine may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
3,4-MethylenedioxymethamphetamineTriflupromazine may decrease the stimulatory activities of 3,4-Methylenedioxymethamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineTriflupromazine may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
5'-Deoxy-5'-MethylthioadenosineThe serum concentration of Triflupromazine can be increased when it is combined with 5'-Deoxy-5'-Methylthioadenosine.Experimental
7-NitroindazoleThe risk or severity of adverse effects can be increased when Triflupromazine is combined with 7-Nitroindazole.Experimental
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Triflupromazine.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Aceprometazine.Approved
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Triflupromazine.Approved
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Triflupromazine.Approved, Vet Approved
adipiplonThe risk or severity of adverse effects can be increased when Triflupromazine is combined with adipiplon.Investigational
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Triflupromazine.Approved
AgomelatineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Agomelatine.Approved, Investigational
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Triflupromazine.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Alfentanil.Approved, Illicit
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Triflupromazine.Approved, Investigational
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Triflupromazine.Approved, Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Alphacetylmethadol.Experimental, Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Triflupromazine.Approved, Illicit, Investigational
AlprenololTriflupromazine may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
Aluminum hydroxideAluminum hydroxide can cause a decrease in the absorption of Triflupromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Aluminum phosphateAluminum phosphate can cause a decrease in the absorption of Triflupromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Triflupromazine.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Amisulpride.Approved, Investigational
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Triflupromazine.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Amobarbital.Approved, Illicit
AmodiaquineThe serum concentration of Triflupromazine can be increased when it is combined with Amodiaquine.Approved
AmoxapineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Amperozide.Experimental
AmphetamineTriflupromazine may decrease the stimulatory activities of Amphetamine.Approved, Illicit
Aop200704Triflupromazine may increase the hypotensive activities of Aop200704.Investigational
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Triflupromazine.Approved
AripiprazoleThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Aripiprazole.Approved, Investigational
ArotinololTriflupromazine may increase the hypotensive activities of Arotinolol.Approved
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Triflupromazine.Approved, Investigational
ArtemetherThe serum concentration of Triflupromazine can be increased when it is combined with Artemether.Approved
ArtemisininThe serum concentration of Triflupromazine can be increased when it is combined with Artemisinin.Investigational
ArtesunateThe serum concentration of Triflupromazine can be increased when it is combined with Artesunate.Approved
ArticaineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Asenapine.Approved
AtazanavirThe serum concentration of Atazanavir can be increased when it is combined with Triflupromazine.Approved, Investigational
AtenololThe serum concentration of Atenolol can be increased when it is combined with Triflupromazine.Approved
AtovaquoneThe serum concentration of Triflupromazine can be increased when it is combined with Atovaquone.Approved
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Triflupromazine.Approved, Investigational
AzaperoneThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Azaperone.Vet Approved
AzelastineTriflupromazine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Baclofen.Approved
BarbitalThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Barbital.Illicit
BefunololTriflupromazine may increase the hypotensive activities of Befunolol.Experimental
BenperidolThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Benzocaine.Approved
BenzphetamineTriflupromazine may decrease the stimulatory activities of Benzphetamine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Benzyl alcohol.Approved
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Triflupromazine.Approved, Vet Approved
BetaxololTriflupromazine may increase the hypotensive activities of Betaxolol.Approved
Betulinic AcidThe serum concentration of Triflupromazine can be increased when it is combined with Betulinic Acid.Investigational
BevantololTriflupromazine may increase the hypotensive activities of Bevantolol.Approved
BezitramideTriflupromazine may increase the hypotensive activities of Bezitramide.Experimental, Illicit, Withdrawn
Bismuth SubcitrateBismuth Subcitrate can cause a decrease in the absorption of Triflupromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
BisoprololTriflupromazine may increase the hypotensive activities of Bisoprolol.Approved
BoceprevirThe serum concentration of Boceprevir can be increased when it is combined with Triflupromazine.Approved
BopindololTriflupromazine may increase the hypotensive activities of Bopindolol.Approved
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Triflupromazine.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Triflupromazine.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Brexpiprazole.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Brimonidine.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Triflupromazine.Approved
BromazepamThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Bromazepam.Approved, Illicit
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Triflupromazine.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Brotizolam.Approved, Withdrawn
BucindololTriflupromazine may increase the hypotensive activities of Bucindolol.Investigational
BufuralolTriflupromazine may increase the hypotensive activities of Bufuralol.Experimental, Investigational
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Triflupromazine.Approved, Investigational
BupranololTriflupromazine may increase the hypotensive activities of Bupranolol.Approved
BuprenorphineTriflupromazine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Triflupromazine.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Triflupromazine.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Butorphanol.Approved, Illicit, Vet Approved
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Triflupromazine.Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Triflupromazine.Approved
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Triflupromazine.Approved
Calcium carbonateCalcium carbonate can cause a decrease in the absorption of Triflupromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Triflupromazine.Experimental
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Triflupromazine.Approved
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Triflupromazine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Carfentanil.Illicit, Vet Approved
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Triflupromazine.Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Carisoprodol.Approved
CarteololTriflupromazine may increase the hypotensive activities of Carteolol.Approved
CarvedilolTriflupromazine may increase the hypotensive activities of Carvedilol.Approved, Investigational
CeliprololTriflupromazine may increase the hypotensive activities of Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Ceritinib can be increased when it is combined with Triflupromazine.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Triflupromazine.Withdrawn
CetirizineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Triflupromazine.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Chlormezanone.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Chloroprocaine.Approved
ChloroquineThe serum concentration of Triflupromazine can be increased when it is combined with Chloroquine.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Chlorphenamine.Approved
ChlorphentermineTriflupromazine may decrease the stimulatory activities of Chlorphentermine.Illicit, Withdrawn
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Triflupromazine.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Chlorprothixene.Approved, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Chlorzoxazone.Approved
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Triflupromazine.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Cinchocaine.Approved, Vet Approved
CiprofloxacinThe serum concentration of Ciprofloxacin can be increased when it is combined with Triflupromazine.Approved, Investigational
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Triflupromazine.Approved
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Triflupromazine.Approved
ClarithromycinThe serum concentration of Clarithromycin can be increased when it is combined with Triflupromazine.Approved
ClemastineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Clidinium.Approved
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Triflupromazine.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Triflupromazine is combined with clomethiazole.Investigational
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Triflupromazine.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Clonazepam.Approved, Illicit
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Triflupromazine.Approved
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Triflupromazine.Approved, Nutraceutical
ClorazepateThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Clorazepate.Approved, Illicit
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Triflupromazine.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Triflupromazine.Approved
CocaineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Triflupromazine.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Triflupromazine.Approved
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Triflupromazine.Approved
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Triflupromazine.Approved
CyclizineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Cyclobenzaprine.Approved
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Triflupromazine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Cyproheptadine.Approved
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Triflupromazine.Approved
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Triflupromazine.Approved
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Triflupromazine.Approved
DantroleneThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Dantrolene.Approved
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Triflupromazine.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Triflupromazine.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Dapoxetine.Investigational
DapsoneThe serum concentration of Triflupromazine can be increased when it is combined with Dapsone.Approved, Investigational
DasatinibThe serum concentration of Dasatinib can be increased when it is combined with Triflupromazine.Approved, Investigational
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Triflupromazine.Approved
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Triflupromazine.Approved
deramciclaneThe risk or severity of adverse effects can be increased when Triflupromazine is combined with deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Desflurane.Approved
DesipramineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Triflupromazine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Detomidine.Vet Approved
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Triflupromazine.Approved, Investigational, Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Dexmedetomidine.Approved, Vet Approved
DextroamphetamineTriflupromazine may decrease the stimulatory activities of Dextroamphetamine.Approved, Illicit
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Triflupromazine.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Dextropropoxyphene.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Dezocine.Approved
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Triflupromazine.Approved, Illicit, Vet Approved
DiethylpropionTriflupromazine may decrease the stimulatory activities of Diethylpropion.Approved, Illicit
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Triflupromazine.Approved
DifenoxinThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Difenoxin.Approved, Illicit
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Triflupromazine.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Triflupromazine.Approved
DihydroartemisininThe serum concentration of Triflupromazine can be increased when it is combined with Dihydroartemisinin.Approved
DihydrocodeineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Dihydrocodeine.Approved, Illicit
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Triflupromazine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Dihydromorphine.Experimental, Illicit
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Triflupromazine.Illicit
DiltiazemThe serum concentration of Diltiazem can be increased when it is combined with Triflupromazine.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Diphenhydramine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Diphenoxylate.Approved, Illicit
DipyridamoleThe serum concentration of Dipyridamole can be increased when it is combined with Triflupromazine.Approved
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Triflupromazine.Approved, Investigational
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Triflupromazine.Approved, Investigational, Vet Approved
DoramectinThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Doramectin.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Doxepin.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Triflupromazine.Approved, Investigational
DoxycyclineThe serum concentration of Triflupromazine can be increased when it is combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Triflupromazine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Triflupromazine is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Triflupromazine.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Triflupromazine.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Drotebanol.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Triflupromazine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Dyclonine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Ecgonine.Experimental, Illicit
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Triflupromazine is combined with ECGONINE METHYL ESTER.Experimental
EcopipamThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Ecopipam.Investigational
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Triflupromazine.Approved
EfavirenzThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Efavirenz.Approved, Investigational
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Triflupromazine.Approved, Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Triflupromazine.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Entacapone.Approved, Investigational
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Triflupromazine.Approved, Investigational
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Triflupromazine.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Triflupromazine.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Triflupromazine.Approved
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Triflupromazine.Approved, Investigational
ErythromycinThe serum concentration of Erythromycin can be increased when it is combined with Triflupromazine.Approved, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Escitalopram.Approved, Investigational
EsmololTriflupromazine may increase the hypotensive activities of Esmolol.Approved
EstazolamThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Estazolam.Approved, Illicit
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Triflupromazine.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Estriol can be increased when it is combined with Triflupromazine.Approved, Vet Approved
EstroneThe serum concentration of Estrone can be increased when it is combined with Triflupromazine.Approved
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Triflupromazine.Approved
EthanolTriflupromazine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Triflupromazine.Approved, Illicit, Withdrawn
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Triflupromazine.Approved
EthosuximideThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Ethyl carbamate.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Etifoxine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Triflupromazine.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Etoperidone.Approved
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Triflupromazine.Approved
EtorphineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Etorphine.Illicit, Vet Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Triflupromazine.Approved
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Triflupromazine.Approved
EzogabineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Fencamfamine.Approved, Illicit, Withdrawn
FenfluramineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Fenfluramine.Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Triflupromazine.Approved
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Triflupromazine.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Triflupromazine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Flibanserin.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Flunitrazepam.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Fluphenazine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Flurazepam.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Fluspirilene.Approved
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Triflupromazine.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Fluticasone Propionate.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Fluvoxamine.Approved, Investigational
FosphenytoinThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Fospropofol.Approved, Illicit
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Triflupromazine.Approved, Investigational
GabapentinThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Gabapentin.Approved, Investigational
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Triflupromazine is combined with gabapentin enacarbil.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Gamma Hydroxybutyric Acid.Approved, Illicit
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Triflupromazine.Approved, Investigational
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Triflupromazine.Approved
GepironeThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Glutethimide.Approved, Illicit
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Triflupromazine.Approved
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Triflupromazine.Withdrawn
GuanfacineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Halazepam.Approved, Illicit, Withdrawn
HalofantrineThe serum concentration of Triflupromazine can be increased when it is combined with Halofantrine.Approved
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Triflupromazine.Approved
HalothaneThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Halothane.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Heroin.Approved, Illicit
HexobarbitalThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Hexobarbital.Approved
HydrocodoneTriflupromazine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Triflupromazine.Approved, Vet Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Triflupromazine.Approved, Illicit
Hydroxyamphetamine hydrobromideTriflupromazine may decrease the stimulatory activities of Hydroxyamphetamine hydrobromide.Approved
HydroxychloroquineThe serum concentration of Triflupromazine can be increased when it is combined with Hydroxychloroquine.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Triflupromazine.Approved
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Triflupromazine.Approved
IdelalisibThe serum concentration of Idelalisib can be increased when it is combined with Triflupromazine.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Iloperidone.Approved
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Triflupromazine.Approved
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Triflupromazine.Approved
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Triflupromazine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Indalpine.Investigational, Withdrawn
IndenololTriflupromazine may increase the hypotensive activities of Indenolol.Withdrawn
IndinavirThe serum concentration of Indinavir can be increased when it is combined with Triflupromazine.Approved
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Triflupromazine.Approved, Investigational
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Triflupromazine.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Triflupromazine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Isoflurane.Approved, Vet Approved
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Triflupromazine.Approved, Vet Approved
KetamineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Ketamine.Approved, Vet Approved
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Triflupromazine.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Ketobemidone.Approved
KetoconazoleThe serum concentration of Ketoconazole can be increased when it is combined with Triflupromazine.Approved, Investigational
LabetalolTriflupromazine may increase the hypotensive activities of Labetalol.Approved
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Triflupromazine.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Triflupromazine.Approved, Investigational
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Triflupromazine.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Triflupromazine.Approved
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Triflupromazine.Approved
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Triflupromazine.Approved
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Triflupromazine.Approved, Investigational
LevobunololTriflupromazine may increase the hypotensive activities of Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Levobupivacaine.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Levodopa.Approved
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Triflupromazine.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Levomethadyl Acetate.Approved
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Triflupromazine.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Levorphanol.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Triflupromazine.Approved, Vet Approved
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Triflupromazine.Approved
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Triflupromazine.Approved, Investigational
LisdexamfetamineTriflupromazine may decrease the stimulatory activities of Lisdexamfetamine.Approved, Investigational
LithiumLithium may increase the neurotoxic activities of Triflupromazine.Approved
LofentanilThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Lofentanil.Illicit
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Triflupromazine.Approved
LoratadineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Triflupromazine.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Triflupromazine.Approved
LosartanThe serum concentration of Losartan can be increased when it is combined with Triflupromazine.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Triflupromazine.Approved
Lu AA21004The risk or severity of adverse effects can be increased when Triflupromazine is combined with Lu AA21004.Investigational
LumefantrineThe serum concentration of Triflupromazine can be increased when it is combined with Lumefantrine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Lurasidone.Approved
MagaldrateMagaldrate can cause a decrease in the absorption of Triflupromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
Magnesium carbonateMagnesium carbonate can cause a decrease in the absorption of Triflupromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium hydroxideMagnesium hydroxide can cause a decrease in the absorption of Triflupromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium oxideMagnesium oxide can cause a decrease in the absorption of Triflupromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Triflupromazine.Approved, Vet Approved
Magnesium TrisilicateMagnesium Trisilicate can cause a decrease in the absorption of Triflupromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
MannitolThe serum concentration of Mannitol can be increased when it is combined with Triflupromazine.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Maprotiline.Approved
MeclizineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Meclizine.Approved
MedetomidineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Medetomidine.Vet Approved
MefloquineThe serum concentration of Triflupromazine can be increased when it is combined with Mefloquine.Approved
MelatoninThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Melperone.Approved
MephedroneTriflupromazine may decrease the stimulatory activities of Mephedrone.Investigational
MephentermineTriflupromazine may decrease the stimulatory activities of Mephentermine.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Triflupromazine.Approved, Illicit
MequitazineTriflupromazine may increase the arrhythmogenic activities of Mequitazine.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Mesoridazine.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Metaxalone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Triflupromazine.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Methadyl Acetate.Approved, Illicit
MethamphetamineTriflupromazine may decrease the stimulatory activities of Methamphetamine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Methaqualone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Triflupromazine.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Triflupromazine.Approved
MethotrimeprazineTriflupromazine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Methoxyflurane.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Methsuximide.Approved
MethylphenidateThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Methylphenidate.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Methylphenobarbital.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Triflupromazine.Approved, Vet Approved
MetipranololTriflupromazine may increase the hypotensive activities of Metipranolol.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Triflupromazine.Approved, Investigational
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Triflupromazine.Approved, Investigational
MetyrosineTriflupromazine may increase the sedative activities of Metyrosine.Approved
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Triflupromazine.Approved, Illicit
MilnacipranThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Milnacipran.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Triflupromazine.Approved, Investigational
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Triflupromazine.Approved
MirtazapineTriflupromazine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Triflupromazine.Approved, Investigational
MizoribineThe serum concentration of Triflupromazine can be increased when it is combined with Mizoribine.Investigational
MMDATriflupromazine may decrease the stimulatory activities of MMDA.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Triflupromazine.Approved
MolindoneThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Molindone.Approved
MorphineThe serum concentration of Morphine can be increased when it is combined with Triflupromazine.Approved, Investigational
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Triflupromazine.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Triflupromazine.Approved, Investigational
NadololThe serum concentration of Nadolol can be increased when it is combined with Triflupromazine.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Nalbuphine.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Triflupromazine.Approved
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Triflupromazine.Approved, Vet Approved
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Triflupromazine.Approved, Investigational
NefazodoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Triflupromazine.Approved, Withdrawn
NelfinavirThe serum concentration of Nelfinavir can be increased when it is combined with Triflupromazine.Approved
NicardipineThe serum concentration of Nicardipine can be increased when it is combined with Triflupromazine.Approved
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Triflupromazine.Approved
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Triflupromazine.Approved, Investigational
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Triflupromazine.Approved
NitrazepamThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Nitrazepam.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Nitrous oxide.Approved, Vet Approved
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Triflupromazine.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Nortriptyline.Approved
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Triflupromazine.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Olopatadine.Approved
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Triflupromazine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Ondansetron.Approved
OpiumThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Opium.Approved, Illicit
OrphenadrineTriflupromazine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Osimertinib can be increased when it is combined with Triflupromazine.Approved
OxazepamThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Oxazepam.Approved
OxetacaineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Oxetacaine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Oxybuprocaine.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Triflupromazine.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Oxymorphone.Approved, Investigational, Vet Approved
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Triflupromazine.Approved, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Paliperidone.Approved
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Triflupromazine.Approved, Investigational
ParaldehydeTriflupromazine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Paroxetine.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Triflupromazine.Approved
PenbutololTriflupromazine may increase the hypotensive activities of Penbutolol.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Pentazocine.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Triflupromazine.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Triflupromazine.Approved
PerazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Perazine.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Perphenazine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Triflupromazine.Approved
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Triflupromazine.Approved
PhenobarbitalThe serum concentration of Phenobarbital can be increased when it is combined with Triflupromazine.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Phenoxyethanol.Approved
PhentermineTriflupromazine may decrease the stimulatory activities of Phentermine.Approved, Illicit
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Triflupromazine.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Pimozide.Approved
PindololTriflupromazine may increase the hypotensive activities of Pindolol.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Pipamperone.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Pipotiazine.Approved
PiritramideThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Piritramide.Investigational
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Triflupromazine.Approved
PizotifenThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Pizotifen.Approved
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Triflupromazine.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Triflupromazine.Approved
PractololTriflupromazine may increase the hypotensive activities of Practolol.Approved
PramipexoleTriflupromazine may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Pramocaine.Approved
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Triflupromazine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Prazepam.Approved, Illicit
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Triflupromazine.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Triflupromazine.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Triflupromazine.Approved, Vet Approved
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Triflupromazine.Approved, Illicit, Investigational
PregnanoloneThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Pregnanolone.Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Prilocaine.Approved
PrimaquineThe serum concentration of Triflupromazine can be increased when it is combined with Primaquine.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Procaine.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Triflupromazine.Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Triflupromazine.Approved, Vet Approved
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Triflupromazine.Approved, Vet Approved
ProguanilThe serum concentration of Triflupromazine can be increased when it is combined with Proguanil.Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Triflupromazine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Promethazine.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Proparacaine.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Propofol.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Propoxycaine.Approved
PropranololThe serum concentration of Propranolol can be increased when it is combined with Triflupromazine.Approved, Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Protriptyline.Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Triflupromazine.Approved
PSD502The risk or severity of adverse effects can be increased when Triflupromazine is combined with PSD502.Investigational
PseudoephedrineTriflupromazine may decrease the stimulatory activities of Pseudoephedrine.Approved
PyrimethamineThe serum concentration of Triflupromazine can be increased when it is combined with Pyrimethamine.Approved, Vet Approved
PyronaridineThe serum concentration of Triflupromazine can be increased when it is combined with Pyronaridine.Investigational
QuazepamThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Quazepam.Approved, Illicit
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Triflupromazine.Approved
QuinacrineThe serum concentration of Triflupromazine can be increased when it is combined with Quinacrine.Approved
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Triflupromazine.Approved
QuinidineThe serum concentration of Triflupromazine can be increased when it is combined with Quinidine.Approved
QuinineThe serum concentration of Triflupromazine can be increased when it is combined with Quinine.Approved
RacloprideThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Raclopride.Investigational
RadicicolThe serum concentration of Triflupromazine can be increased when it is combined with Radicicol.Experimental
RamelteonThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Ramelteon.Approved, Investigational
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Triflupromazine.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Triflupromazine.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Triflupromazine.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Remifentanil.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Triflupromazine.Approved, Withdrawn
ReserpineThe serum concentration of Reserpine can be increased when it is combined with Triflupromazine.Approved
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Triflupromazine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Triflupromazine.Approved, Investigational
RisperidoneThe serum concentration of Risperidone can be increased when it is combined with Triflupromazine.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Ritanserin.Investigational
RitobegronTriflupromazine may decrease the stimulatory activities of Ritobegron.Investigational
RitonavirThe serum concentration of Ritonavir can be increased when it is combined with Triflupromazine.Approved, Investigational
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Triflupromazine.Approved
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Triflupromazine.Approved
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Triflupromazine.Approved, Investigational
RomifidineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Romifidine.Vet Approved
RopiniroleTriflupromazine may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Triflupromazine.Approved
RotigotineTriflupromazine may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Triflupromazine.Approved
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Triflupromazine is combined with S-Ethylisothiourea.Experimental
Sage 547The risk or severity of adverse effects can be increased when Triflupromazine is combined with Sage 547.Investigational
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Triflupromazine.Approved, Vet Approved
SaquinavirThe serum concentration of Saquinavir can be increased when it is combined with Triflupromazine.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Triflupromazine.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Triflupromazine.Approved, Investigational, Vet Approved
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Triflupromazine.Approved
SertindoleThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Sertindole.Approved, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Sevoflurane.Approved, Vet Approved
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Triflupromazine.Approved
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Triflupromazine.Approved
SinefunginThe serum concentration of Triflupromazine can be increased when it is combined with Sinefungin.Experimental
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Triflupromazine.Approved, Investigational
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Triflupromazine.Approved
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Triflupromazine.Approved
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Triflupromazine.Approved, Investigational
SotalolTriflupromazine may increase the hypotensive activities of Sotalol.Approved
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Triflupromazine.Approved
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Triflupromazine.Experimental
StiripentolThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Sufentanil.Approved, Investigational
SulfadoxineThe serum concentration of Triflupromazine can be increased when it is combined with Sulfadoxine.Approved
SulfametopyrazineThe serum concentration of Triflupromazine can be increased when it is combined with Sulfametopyrazine.Approved, Withdrawn
SulpirideThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Sulpiride.Approved
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Triflupromazine.Approved, Investigational
SuvorexantTriflupromazine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Triflupromazine.Approved, Investigational
tafenoquineThe serum concentration of Triflupromazine can be increased when it is combined with tafenoquine.Investigational
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Triflupromazine.Approved
TandospironeThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Triflupromazine.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Tasimelteon.Approved
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Triflupromazine.Experimental
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Triflupromazine.Approved
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Triflupromazine.Approved
TelaprevirThe serum concentration of Telaprevir can be increased when it is combined with Triflupromazine.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Triflupromazine.Approved
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Triflupromazine.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Triflupromazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Tetracaine.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Tetrodotoxin.Investigational
ThalidomideTriflupromazine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Thiamylal.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Thiopental.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Thioridazine.Approved
ThiothixeneThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Thiothixene.Approved
TiagabineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Tiapride.Investigational
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Triflupromazine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Tiletamine.Vet Approved
TimololThe serum concentration of Timolol can be increased when it is combined with Triflupromazine.Approved
TizanidineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Tizanidine.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Tolcapone.Approved, Withdrawn
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Triflupromazine.Approved
TopiramateThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Topiramate.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Triflupromazine.Approved, Investigational
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Triflupromazine.Approved, Investigational
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Triflupromazine.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Tranylcypromine.Approved
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Triflupromazine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Trazodone.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Triazolam.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Trifluoperazine.Approved
TrimethoprimThe serum concentration of Triflupromazine can be increased when it is combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Triprolidine.Approved
Uc1010The risk or severity of adverse effects can be increased when Triflupromazine is combined with Uc1010.Investigational
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Triflupromazine.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Triflupromazine.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Triflupromazine.Approved, Investigational
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Triflupromazine.Approved
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Triflupromazine.Approved
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Triflupromazine.Approved
VerapamilThe serum concentration of Verapamil can be increased when it is combined with Triflupromazine.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Vigabatrin.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Vilazodone.Approved
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Triflupromazine.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Triflupromazine.Approved, Investigational
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Triflupromazine.Approved
VortioxetineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Vortioxetine.Approved
XylazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Zaleplon.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Ziconotide.Approved
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Triflupromazine.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Triflupromazine.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Zolazepam.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Triflupromazine.Approved, Investigational
ZolpidemTriflupromazine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Zopiclone.Approved
ZotepineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Zotepine.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Zuclopenthixol.Approved, Investigational
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesN05AA05
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9926
Blood Brain Barrier+0.9839
Caco-2 permeable+0.7847
P-glycoprotein substrateSubstrate0.7862
P-glycoprotein inhibitor IInhibitor0.8563
P-glycoprotein inhibitor IIInhibitor0.8737
Renal organic cation transporterInhibitor0.6721
CYP450 2C9 substrateNon-substrate0.7813
CYP450 2D6 substrateSubstrate0.5115
CYP450 3A4 substrateSubstrate0.5822
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorNon-inhibitor0.9141
CYP450 2D6 inhibitorInhibitor0.8932
CYP450 2C19 inhibitorNon-inhibitor0.8156
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.6166
Ames testNon AMES toxic0.875
CarcinogenicityNon-carcinogens0.9349
BiodegradationNot ready biodegradable1.0
Rat acute toxicity3.2485 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9849
hERG inhibition (predictor II)Inhibitor0.8433
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
logP5.54BIOBYTE (1995)
logS-5.3ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.0018 mg/mLALOGPS
logP4.95ALOGPS
logP4.81ChemAxon
logS-5.3ALOGPS
pKa (Strongest Basic)9.2ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area6.48 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity94.93 m3·mol-1ChemAxon
Polarizability35.29 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (7.91 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-0a4i-9121000000-0dfbd5aaf88b987dbe84View in MoNA
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenothiazines. These are polycyclic aromatic compounds containing a phenothiazine moiety, which is a linear tricyclic system that consists of a two benzene rings joined by a para-thiazine ring.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzothiazines
Sub ClassPhenothiazines
Direct ParentPhenothiazines
Alternative Parents
Substituents
  • Phenothiazine
  • Alkyldiarylamine
  • Diarylthioether
  • Benzenoid
  • Para-thiazine
  • Tertiary aliphatic amine
  • Tertiary amine
  • Azacycle
  • Thioether
  • Hydrocarbon derivative
  • Organonitrogen compound
  • Organofluoride
  • Organohalogen compound
  • Amine
  • Alkyl halide
  • Alkyl fluoride
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name:
DRD1
Uniprot ID:
P21728
Molecular Weight:
49292.765 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Potassium channel regulator activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name:
DRD2
Uniprot ID:
P14416
Molecular Weight:
50618.91 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various ergot alkaloid derivatives and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. Beta-arrestin family members inhibit signaling via G proteins ...
Gene Name:
HTR2B
Uniprot ID:
P41595
Molecular Weight:
54297.41 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Cooper M, Wyllie JH: Some properties of 5-hydroxytryptamine receptors in the hindquarters of the rat. Br J Pharmacol. 1979 Sep;67(1):79-85. [PubMed:497523 ]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM1
Uniprot ID:
P11229
Molecular Weight:
51420.375 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Snyder S, Greenberg D, Yamamura HI: Antischizophrenic drugs and brain cholinergic receptors. Affinity for muscarinic sites predicts extrapyramidal effects. Arch Gen Psychiatry. 1974 Jul;31(1):58-61. [PubMed:4152054 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
G-protein coupled acetylcholine receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is adenylate cyclase inhibition. Signaling promotes phospholipase C activity, leading to the release of inositol trisphosphate (IP3); this then trigge...
Gene Name:
CHRM2
Uniprot ID:
P08172
Molecular Weight:
51714.605 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Snyder S, Greenberg D, Yamamura HI: Antischizophrenic drugs and brain cholinergic receptors. Affinity for muscarinic sites predicts extrapyramidal effects. Arch Gen Psychiatry. 1974 Jul;31(1):58-61. [PubMed:4152054 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Identical protein binding
Specific Function:
Esterase with broad substrate specificity. Contributes to the inactivation of the neurotransmitter acetylcholine. Can degrade neurotoxic organophosphate esters.
Gene Name:
BCHE
Uniprot ID:
P06276
Molecular Weight:
68417.575 Da
References
  1. Muraoka S, Miura T: Inactivation of cholinesterase induced by chlorpromazine cation radicals. Pharmacol Toxicol. 2003 Feb;92(2):100-4. [PubMed:12747580 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Ibrahim S, Peggins J, Knapton A, Licht T, Aszalos A: Influence of antipsychotic, antiemetic, and Ca(2+) channel blocker drugs on the cellular accumulation of the anticancer drug daunorubicin: P-glycoprotein modulation. J Pharmacol Exp Ther. 2000 Dec;295(3):1276-83. [PubMed:11082465 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 08, 2016 11:46